References in this Annual Report to the �company,� �we,� �us� or �our� refer to
CytRx Corporation, unless otherwise indicated.
We are a biopharmaceutical research and development company specializing in
oncology. We currently are focused on the clinical development of aldoxorubicin
(formerly known as INNO-206), our modified version of the widely-used
chemotherapeutic agent, doxorubicin. We recently reported top-line efficacy
results (median progression-free survival, progression-free survival at six
months, overall response rates and hazard ratios) of our Phase 2b clinical trial
with aldoxorubicin as a treatment for soft tissue sarcoma, or STS. Hazard ratios
- the likelihood that the study endpoint (in this case tumor progression) will
be reached during a given period - are an important measure of the reliability
and uniformity of the absolute data for progression-free survival, or PFS.